Use of 2-methylene-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 to increase bone strength

Abstract

This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 . This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. This compound also increases both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.

1 . A method of treating metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3  having the formula:  
     
       
         
         
             
             
         
       
     
   
   
       2 . The method of  claim 1  where the disease is senile osteoporosis.  
   
   
       3 . The method of  claim 1  where the disease is postmenopausal osteoporosis.  
   
   
       4 . The method of  claim 1  where the disease is steroid-induced osteoporosis.  
   
   
       5 . The method of  claim 1  where the disease is a low bone turnover osteoporosis.  
   
   
       6 . The method of  claim 1  where the disease is osteomalacia.  
   
   
       7 . The method of  claim 1  where the disease is renal osteodystrophy.  
   
   
       8 . The method of  claim 1  wherein 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3  is administered orally.  
   
   
       9 . The method of  claim 1  wherein 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3  is administered parenterally.  
   
   
       10 . The method of  claim 1  wherein 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3  is administered transdermally.  
   
   
       11 . The method of  claim 1  wherein 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3  is administered in a dosage of from 0.1 μg to 10 μg per day.  
   
   
       12 - 29 . (canceled)